Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

110 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Has the 6-min walk distance run its course?
McLaughlin VV. McLaughlin VV. Chest. 2012 Dec;142(6):1363-1365. doi: 10.1378/chest.12-1110. Chest. 2012. PMID: 23208324 No abstract available.
Medical management of primary pulmonary hypertension.
McLaughlin VV. McLaughlin VV. Expert Opin Pharmacother. 2002 Feb;3(2):159-65. doi: 10.1517/14656566.3.2.159. Expert Opin Pharmacother. 2002. PMID: 11829729 Review.
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Barst RJ, et al. Among authors: mclaughlin v. Chest. 2002 Jun;121(6):1860-8. doi: 10.1378/chest.121.6.1860. Chest. 2002. PMID: 12065350 Clinical Trial.
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
McLaughlin VV, Shillington A, Rich S. McLaughlin VV, et al. Circulation. 2002 Sep 17;106(12):1477-82. doi: 10.1161/01.cir.0000029100.82385.58. Circulation. 2002. PMID: 12234951 Clinical Trial.
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S; Treprostinil Study Group. McLaughlin VV, et al. J Cardiovasc Pharmacol. 2003 Feb;41(2):293-9. doi: 10.1097/00005344-200302000-00019. J Cardiovasc Pharmacol. 2003. PMID: 12548091 Clinical Trial.
Successful management of pregnancy in a patient with eisenmenger syndrome with epoprostenol.
Geohas C, McLaughlin VV. Geohas C, et al. Among authors: mclaughlin vv. Chest. 2003 Sep;124(3):1170-3. doi: 10.1378/chest.124.3.1170. Chest. 2003. PMID: 12970054
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV; American College of Chest Physicians. Badesch DB, et al. Among authors: mclaughlin vv. Chest. 2004 Jul;126(1 Suppl):35S-62S. doi: 10.1378/chest.126.1_suppl.35S. Chest. 2004. PMID: 15249494
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn G; American College of Chest Physicians. McLaughlin VV, et al. Chest. 2004 Jul;126(1 Suppl):78S-92S. doi: 10.1378/chest.126.1_suppl.78S. Chest. 2004. PMID: 15249497 Review.
Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension.
Benisty JI, McLaughlin VV, Landzberg MJ, Rich JD, Newburger JW, Rich S, Folkman J. Benisty JI, et al. Among authors: mclaughlin vv. Chest. 2004 Oct;126(4):1255-61. doi: 10.1378/chest.126.4.1255. Chest. 2004. PMID: 15486390
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ. Tapson VF, et al. Among authors: mclaughlin vv. Chest. 2006 Mar;129(3):683-8. doi: 10.1378/chest.129.3.683. Chest. 2006. PMID: 16537868 Clinical Trial.
110 results
Jump to page
Feedback